CARLSBAD, CA - Palisade Bio, Inc. (NASDAQ: PALI), a biopharmaceutical company, has announced the successful refinement of patient selection strategies for its lead program PALI-2108, a colon-specific PDE4 inhibitor prodrug aimed at treating Ulcerative Colitis (UC). The company, in collaboration with Strand Life Sciences, utilized RNAseq datasets to pinpoint PDE4B expression as a key biomarker in UC patients, with over-expression observed in 70% of adult and 90% of pediatric patients with moderate to severe conditions.
This development in patient stratification could enhance the precision of treatment for UC, a chronic inflammatory bowel disease. Dr. Mitch Jones, CMO of Palisade Bio, commented on the potential of PDE4B to serve as an important tool in personalized medicine for colitis, allowing for more effective treatment approaches.
The preclinical data also revealed that PALI-2108 reduced PDE4B expression in a DSS-induced UC mouse model, correlating with increased colon tissue cAMP levels and decreased inflammatory cytokines, such as TNF-alpha. The treatment showed a significant reduction in disease activity index scores and mitigated symptoms like body weight loss and changes in colon length.
Palisade Bio plans to initiate a Phase 1 human clinical trial for PALI-2108 before the end of the year, signaling a step forward in the company's commitment to address autoimmune, inflammatory, and fibrotic diseases.
The information in this article is based on a press release statement from Palisade Bio. The company's forward-looking statements include expectations around the development and potential market for PALI-2108, among other aspects of their operations. However, these statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
In other recent news, Palisade Bio has made substantial progress on its lead drug candidate, PALI-2108, setting the dose for Phase 1 trials aimed at treating Ulcerative Colitis. The biopharmaceutical company has successfully manufactured the first GMP batch of PALI-2108, demonstrating readiness for the upcoming trials. In a strategic collaboration with Strand Life Sciences, potential PDE4-related biomarkers for Ulcerative Colitis treatment have been identified, pushing forward the company's precision medicine initiative.
Further, Palisade Bio has secured a European patent for its innovative therapeutics targeting inflammatory bowel diseases, including PALI-2108 and PALI-1908. The company's shareholders recently elected three directors and ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Analysts from Ladenburg Thalmann have maintained a Buy rating for Palisade Bio, signaling confidence in the potential of PALI-2108. These developments highlight Palisade Bio's commitment to advancing its drug development efforts and strategic objectives.
InvestingPro Insights
As Palisade Bio, Inc. (NASDAQ: PALI) advances its lead program, PALI-2108, with a focus on Ulcerative Colitis, the financial metrics and analyst insights from InvestingPro paint a comprehensive picture of the company's current market position. With a market capitalization of $4.28 million, Palisade Bio is navigating the competitive biopharmaceutical landscape with a strategic emphasis on innovation and targeted therapies.
InvestingPro Tips suggest that while analysts anticipate sales growth in the current year, they do not expect the company to be profitable within this period. This aligns with the company's aggressive research and development efforts, as evidenced by their latest breakthrough in patient selection strategies. Moreover, the company's balance sheet reflects a cautious approach to financial stability, as it holds more cash than debt, which could provide resilience amid the costly clinical trial phases.
InvestingPro Data underscores the challenges faced by Palisade Bio, with a negative price-to-earnings (P/E) ratio of -0.2, indicating that investors are currently not expecting earnings growth. The company's share price performance has also been underwhelming, with a significant decline of over 65% in the past year. Nevertheless, the company's liquid assets exceed its short-term obligations, which may provide some cushion as it moves forward with clinical trials.
For investors and stakeholders keeping a close eye on Palisade Bio's progress, additional InvestingPro Tips are available, offering deeper insights into the company's financial health and market potential. With 10 more tips listed on InvestingPro, interested parties can further explore the nuanced aspects of Palisade Bio's operational and financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.